|
 |
 |
 |
 |
Name:
Sector:
Chief Executive:
|
Tercica
Healthcare
John Scarlett, MD
|
|
|
Summary:
|
Late-stage biopharmaceutical company focused on the development
and commercialization of therapies to treat endocrine disorders,
including human growth and diabetes. The company's lead product
is recombinant human Insulin-like Growth Factor (IGF-1), a naturally
occurring hormone with broad metabolic activity that has been
shown to have clinically significant effects on both bone growth
and lowering blood glucose in advanced clinical trials.
|
|
|
Stage of Initial
Investment:
|
Venture |
Liquidity:
|
Acquired
by Ipsen (Euronext: IPN)
|
|
|
|
|
|
|
|
 |
| |
2000 Sierra Point Parkway, Suite 400
Brisbane, CA 94005
Phone: 650.624.4900
Fax: 650.624.4940
|
|
 |
|
|
|
